Dr. Linda J. Paradiso, D.V.M., M.B.A., has over 25 years of broad experience in pharmaceutical and emerging biotechnology research and development. She has been involved in the development of new drug/biologic products and medical devices in the areas of cancer, hematology, infectious disease, retinal diseases, pain, and respiratory/pulmonary diseases. She has 25 INDs to her credit and contributed directly to the worldwide development, approval and lifecycle management of the marketed products Viracept®, Penetrex®, Omnicef®, Doxil®, DepoCyt®, Kepivance™, Neulasta™ Aranesp®, Vectibix™ and NPlate™. Dr. Paradiso is President and CEO of a pharmaceutical/biotechnology consulting firm, with past and present clients including Genentech, Amgen, Salmedix, Nanospectra, Tanox, Oncovance, Bellicum, Introgen, America Stem Cell, NanoMedical Systems, Texas A&M University and Baylor College of Medicine Technologies.

Dr. Paradiso served as vice president, clinical and regulatory affairs for Tanox, Inc. (now Genentech). Previously, she was therapy area head for oncology regulatory affairs at Amgen, Inc., where she was responsible for global regulatory strategy for all pre-marketed and marketed oncology products, and head of oncology clinical development for the La Jolla global R&D laboratories of Pfizer. Before that, Dr. Paradiso was head of global clinical research for Agouron Pharmaceuticals (now Pfizer). She has served in clinical and regulatory senior management capacities for other emerging biotechnology companies. She began her career at Warner-Lambert (Parke-Davis) as a toxicologist, and spent 11 years in clinical and research positions of increasing responsibility, including Director positions in oncology and infectious disease clinical development. Dr. Paradiso is a member of the American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH) and Bio-Houston.

Dr. Paradiso earned her Doctor of Veterinary Medicine degree from Michigan State University and a Master of Business Administration degree with emphasis on health care from the University of California-Irvine. She holds two B.S. degrees from the University of Michigan, in Zoology and Natural Resources.

Linda is a former officer of several publicly-traded biotechnology companies, including DepoTech (now SkyePharma), Salmedix (now Cephalon), and Tanox (now Genentech), and is a former director of Amgen, Inc.